How Repair Biotechnologies Enhanced mRNA Efficacy, Cut Costs & Streamlined Clinical Trial Feasibility

Repair Biotechnologies, a pioneering preclinical biotech company, is developing groundbreaking drug therapies aimed at cholesterol and aging-related diseases. Their innovative approach targets chronic conditions such as atherosclerosis, focusing on delivering advanced treatments that address the root causes of these diseases rather than just their symptoms.

After investigating various gene therapy techniques, Repair Biotechnologies selected mRNA-LNP technology as a promising solution to enable cells to clear harmful cholesterol deposits and overcome the limitations of traditional therapies. The company is now preparing for preclinical studies that have the potential to significantly improve the longevity and quality of life for patients suffering from age-related diseases.

Through its deep expertise in mRNA and lipid nanoparticle (LNP) technologies, Vernal is empowering drug developers like Repair Biotechnologies to evaluate and optimize the critical quality attributes (CQAs) of their mRNA-based therapies. This ensures a faster path to the clinic while maintaining confidence in the product’s quality — two essential factors for the success of mRNA programs and the achievement of positive patient outcomes.

Download the full case study below to learn how Repair Biotechnologies enhanced efficacy, reduced costs, and accelerated clinical trials with Vernal Biosciences—setting the stage for the next generation of breakthrough treatments.